or continuing GC therapy, despite the low certainty of the evidence. Initial assessment should occur as soon as possible within 6 months of GC therapy initiation. Clinical fracture risk assessment includes dose, duration, and pattern of GC use, alcohol use, smoking history, hypogonadism, history of prior fractures (traumatic, fragility, asymptomatic), low body weight, significant weight loss, parental history of hip fracture, fall history, thyroid disease, hyperparathyroidism, rheumatoid